Obsidian Therapeutics is a clinical-stage biotechnology company developing engineered cell and gene therapies built on its proprietary cytoDRiVE platform, which uses drug-responsive domains to regulate therapeutic protein function with an FDA-approved small molecule. Its lead program, OBX-115, is in Phase 2 trials for advanced melanoma. - View it on GitHub